PPAR-γ activation by its agonists such as TZDs, has been demonstrated previously to inhibit VSMC proliferation and prevent vascular remodeling in hypertension, restenosis, and atherosclerosis in both early clinical trials and animal experiments[21–24,27]. This evidence concerns the gene PPARG and hypertensive disorder.